Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00655889 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency
A Phase 2 study, sponsored by Castle Creek Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00655889 is a Phase 2 study that has completed, run by Castle Creek Biosciences. The registered enrollment target is 13 participants.
The verdict
NCT00655889, a Phase 2 study, has completed, sponsored by Castle Creek Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM in subjects with maxillary lesions who were treated in a previous study (IT-G-002, no NCT identification number)
Interventions
- BIOLOGICAL Autologous Human Fibroblasts (azficel-T)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00655889
The ClinicalTrials.gov registry entry for NCT00655889 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Castle Creek Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous Human Fibroblasts (azficel-T) is the first listed.
NCT00655889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00655889 about?
NCT00655889 is a clinical study titled "Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency". The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM in subjects with maxillary lesions who were treated in a previous study (IT-G-002, no NCT identification number)
What is the current status of trial NCT00655889?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2006-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00655889?
The interventions under investigation include: Autologous Human Fibroblasts (azficel-T) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00655889?
This trial is sponsored by Castle Creek Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.